1. U.S. Food and Drug Administration (FDA): benefit-risk considerations for cefiderocol (Fetroja);Naseer;Clin Infect Dis,2021
2. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial;Bassetti;L,2020
3. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial;Wunderink;Lancet Infect Dis,2020